Medication info
Memantamax 20mg Tablets (Memantine Hydrochloride)

Memantamax 20mg Tablets (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›20mg / 1 tablet
Manufacturer / importer
Myeongmoon Bio Co., Ltd.
Appearance
White, rectangular film-coated tablets
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202500882 · Approved 2025.04.14 · Insurance code 079700020

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7) Administer 5mg once daily for 7 days. Week 2 (Days 8–14) Administer 10mg once daily for 7 days. Week 3 (Days 15–21) Administer 15mg once daily for 7 days. Starting in Week 4 Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.

Ingredients

Manufacturer
Myeongmoon Bio Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for patients with moderate to severe Alzheimer's disease. Alzheimer's disease is a condition accompanied by memory decline and impaired cognitive function, and this medication helps alleviate these symptoms. It contributes to improving the cognitive function of patients and enhancing their ability to perform daily activities. The goal is to slow the progression of symptoms and improve the quality of life. Therefore, it is used for the treatment of moderate to severe Alzheimer's disease.

How to take

Adult dose

This medicine is administered orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7) Administer 5mg once daily for 7 days. Week 2 (Days 8–14) Administer 10mg once daily for 7 days. Week 3 (Days 15–21) Administer 15mg once daily for 7 days. Starting in Week 4 Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.

Precautions

This medication should not be used by patients who are allergic to its ingredients. Patients with severely impaired liver or kidney function should not take this medication. Individuals with a genetic inability to digest certain sugars should also refrain from using this medication. Those with epilepsy or a history of seizures should use this medication with caution. Taking it with certain neurological medications may increase the risk of side effects, so co-administration should be avoided. Patients with conditions that may alter urine acidity need to be monitored closely. Caution is needed for patients with unmanaged heart disease or hypertension. Side effects such as dizziness, headaches, constipation, drowsiness, and increased blood pressure may occur. Rarely, symptoms such as mental confusion, hallucinations, or delusions may also manifest. Since it may affect the heart or blood vessels, immediate reporting of any symptoms is necessary. Drug interactions may occur, so current medications must be disclosed. Particularly, the risk of side effects may increase when used with neurological agents. Frequent blood tests may be required when taken with anticoagulant medications. Women who are pregnant or may become pregnant should carefully consider the effects on the fetus before taking this medication. If breastfeeding, it is advisable to discontinue nursing, as this medication may pass into breast milk. This drug has not been established for safety and efficacy in children or adolescents under the age of 18, thus should not be used in these populations. Overdose may result in central nervous system symptoms and gastrointestinal symptoms, requiring immediate hospital treatment. As there is no specific antidote, treatment will be symptomatic. This medication may impair reaction time and concentration, necessitating caution when driving or operating machinery. It should be kept out of reach of children, and it is advisable not to transfer it to another container.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucinations
  • psychotic reaction
Show 18 more
  • balance disorder
  • gait disturbance
  • seizures
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function tests
  • hepatitis
  • fatigue
  • nonspecific fatigue
  • weakness
  • diarrhea
  • agitation
  • aggressiveness
  • stupor
  • unconsciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to protect it from air and moisture. Additionally, it is best stored at room temperature, between 1°C and 30°C, avoiding extremes of hot or cold.

Appearance and packaging

Appearance

White, rectangular film-coated tablets

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.